Related Experiment Video

Updated: Jun 23, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough

Nancy E Hynes1, Julien H Dey

  • 1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4059 Basel, Switzerland. nancy.hynes@fmi.ch

Cancer Cell
|May 5, 2009
PubMed

Insights

Trastuzumab disrupts ErbB2/ErbB3/PI3K complexes in breast cancer. However, mutated PI3K can prevent AKT pathway inhibition, explaining treatment resistance in some patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Trastuzumab is a targeted therapy for ErbB2-overexpressing breast cancers.
  • ErbB2 signaling pathways are crucial in breast cancer progression.
  • Understanding resistance mechanisms to Trastuzumab is vital for improving patient outcomes.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying Trastuzumab resistance.
  • To elucidate the role of PI3K mutations in Trastuzumab efficacy.
  • To identify potential therapeutic strategies for overcoming Trastuzumab unresponsiveness.

Main Methods:

  • Analysis of ligand-independent ErbB2/ErbB3/PI3K complexes.
  • Assessment of AKT signaling pathway activity.
  • Investigation of Trastuzumab's effect in the presence of PI3K mutations.

Main Results:

  • Trastuzumab effectively disrupts ErbB2/ErbB3/PI3K complexes and inhibits AKT signaling in ErbB2-overexpressing breast cancer cells.
  • In tumors with mutated PI3K, Trastuzumab-mediated disruption of these complexes does not lead to AKT pathway inhibition.
  • This failure to inhibit AKT signaling in the context of PI3K mutations explains Trastuzumab's ineffectiveness in certain tumors.

Conclusions:

  • The study reveals a key mechanism of Trastuzumab resistance involving PI3K mutations.
  • Targeting the ErbB2/ErbB3/PI3K/AKT axis is critical for Trastuzumab efficacy.
  • Identifying PI3K mutation status may help predict patient response to Trastuzumab therapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...